Connect your AI

LBRX LBRX Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

MapLight Therapeutics, Inc. MPLT

$814K+217%

Zevra Therapeutics, Inc.ZVRA

$624K+105%

Acadia PharmaceuticalsACAD

$453K-78.6%

Septerna, Inc.SEPN

$755K-21.8%

Rapport Therapeutics, Inc.RAPP

$364K-16.5%

Praxis Precision Medicines, Inc.PRAX

$655K-46.7%

Other financials

Income statement

Net income-$19.1M-259%

EPS (diluted)-$0.67+95.5%

Balance sheet

Cash & equivalents$320.7M—

Total debt$3.5M—

Total equity$378.7M+481%

Total assets$393.5M—

Cash flow

Operating cash flow-$23.3M-187%

CapEx$32.0K+52.4%

Free cash flow-$23.3M-186%

Valuation

Market cap$874.06M+159%

Enterprise value$556.86M—

Returns & leverage

Return on equity-27.9%—

Debt / equity0×—

Current ratio35.7×—

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is LBRX's accretion (amortization) of discounts and premiums, investments?: LBRX (LBRX) reported accretion (amortization) of discounts and premiums, investments of -$17K in Q1 2026.
What does accretion (amortization) of discounts and premiums, investments mean?: Measures the non-cash adjustments to the carrying value of investment securities resulting from the amortization of premiums or the accretion of discounts over the life of the instrument. This reflects the effective interest income earned on the company's investment portfolio beyond the stated coupon payments.